Last reviewed · How we verify
Ropivacaine concentration high
Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.
Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses. Used for Local and regional anesthesia for surgical procedures, Peripheral nerve blocks, Epidural anesthesia.
At a glance
| Generic name | Ropivacaine concentration high |
|---|---|
| Sponsor | Oslo University Hospital |
| Drug class | Local anesthetic (amide) |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Ropivacaine reversibly binds to and blocks voltage-gated sodium channels on the inner surface of nerve cell membranes, preventing depolarization and action potential propagation. This results in local anesthesia and loss of sensation in the area where it is administered. As a long-acting amide local anesthetic, it has a slower onset and longer duration compared to shorter-acting agents.
Approved indications
- Local and regional anesthesia for surgical procedures
- Peripheral nerve blocks
- Epidural anesthesia
Common side effects
- Hypotension
- Bradycardia
- Nausea
- Dizziness
- Systemic toxicity (CNS and cardiac effects at high concentrations)
Key clinical trials
- Efficacy of Methylene Blue Plus Ropivacaine for Post-Hemorrhoidectomy Pain. (PHASE4)
- Low Concentration Local Anesthesia Fascia Iliaca Block for Total Hip Arthroplasty (NA)
- Effects of Ropivacaine Concentrations on Prolonged Labor Analgesia (NA)
- Ropivacaine Concentration and Rebound Pain (PHASE4)
- Regional Anesthesia Techniques in Breast Surgery (NA)
- Exploring the Minimum Effective Concentration and Volume of Ropivacaine for Sacral Plexus Anesthesia (PHASE4)
- The Effect of Brachial Plexus Block on Diaphragm Movement (NA)
- High Volume Caudal Study (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ropivacaine concentration high CI brief — competitive landscape report
- Ropivacaine concentration high updates RSS · CI watch RSS
- Oslo University Hospital portfolio CI